Mr. Yong'an Xu, the chairman of Hengdian Group, founded Yong'an Chemical Factory in Dongyangin July 1990. It was later merged with No.1 Dongyang Organic Chemical Factory to establish Hengdian Group Yong'an Chemical General Factory, which developed into the subsidiary Apeloa Tospo Pharmaceutical.

Hengdian Group established Dongyang Organic Synthesis Chemical Factory No. 4, which was later merged with Dongyang Organic Chemical Factory No. 6 and No. 9 to form Dongyang Organic Chemical General Factory, and subsequently developed into the subsidiary Apeloa Jiayuan Pharmaceutical.

Hengdian Group established DongYang Pharmaceutical Chemical Factory, which later merged with Dongyang Pharmaceutical Industry Company to form Dongyang Pharmaceutical and Chemical General Corporation. Subsequently, it developed into the subsidiary Apeloa Kangyu Pharmaceutical.

The first national class II new drug, the Ubenmus capsule, was approved by CFDA(China Food and Drug Administration).

The first API production line passed the GMP inspection.

The company has completed the listing in the Chinese stock market (stock code: SZ 000739).

Passed the FDA on-site inspection for the first time.

The first API product passed the WHO on-site inspection, and the PMDA on-site inspection passed in November 2012.

The Pharmaceutical Research Institute moved into Hangzhou Pharmaceutical Port.

The first generic drug passed the consistency evaluation and won the bid of the national centralized procurement in September 2019.

The CDMO R&D Center (Shanghai) was put into use.

The first API product passed the on-site inspection by the EDQM.

The first ANDA was approved by the US FDA.

Synthetic biology and enzyme catalysis, flow chemistry, Crystallization & Particle Engineering, and peptide technology platforms were established.

The first flow chemistry workshop (commercial scale) was put into use.

The US subsidiary Apeloa Pharma Solutions Co. (APS) was set up.

The first multi-functional CDMO workshopwas put into use and the Process Safety Center passed CNAS certification.

The subsidiary APELOA Europe GmbH was set up.

The Analytical Testing Center passed the CNAS certification; The first Apeloa Scientific Advisory Board is convened.

The first highly potent workshop was put into use.

The Global Innovative R&D and Production Service Platform (CDMO) was completed.

APS’s new R&D center was established in Great Boston.

The 2nd Apeloa Scientific Advisory Board is convened.